Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 435 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lymph Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Load in Blood and Lymph Tissues in People Living With HIV

NCT00001316
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1992
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT01917721
View directory record Official record
Conditions
Kawasaki Disease, Coronary Aneurysm
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Impact of Osteopathic Manipulative Medicine on Sentinal Lymph Node Biopsy Dye and Tracer Uptake

NCT07269860
View directory record Official record
Conditions
Breast Cancer
Interventions
OMM prior to SLNB
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00881361
View directory record Official record
Conditions
Breast Cancer
Interventions
systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Analysis of Parametrial Lymph Nodes as Sentinel Nodes in Patients With Cervical Cancer

NCT00631241
View directory record Official record
Conditions
Cervical Cancer
Interventions
Single Photon Emission Computed Tomography, Intraoperative Lymphatic Mapping
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

NCT05900986
View directory record Official record
Conditions
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Interventions
LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg, LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Weston, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer

NCT00039676
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia, Hodgkin Disease, NonHodgkin Lymphoma, Mixed Lymphoproliferative Disease
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
11 Months and older
Enrollment
1,836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Active, not recruiting Not applicable Interventional

Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer

NCT03786354
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Lymph Node Involvement, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy
Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Recruiting No phase listed Observational

Detection of Genetic Markers of Lung Cancer

NCT00280202
View directory record Official record
Conditions
Lung Cancer
Interventions
Biopsy of the major carinal area, Biopsy of abnormal & suspicious areas of the bronchial tree, Evaluation of the tumor for DNA mutations, Bronchoalveolar Lavage (BAL) for cytokine analysis, Correlation of flow cytometric & RT PCR for TNM stage, Analysis of lymph nodes
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 19, 2026, 5:02 AM EDT
Terminated Not applicable Interventional

Manual Lymph Drainage

NCT02360735
View directory record Official record
Conditions
Total Knee Arthroplasty, Post-operative Edema
Interventions
Manual Lymphatic Drainage, Physical Therapy
Other
Lead sponsor
Anne Arundel Health System Research Institute
Other
Eligibility
45 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Annapolis, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia

NCT02530515
View directory record Official record
Conditions
Anemia, Cancer Fatigue, Chronic Lymphocytic Leukemia, Fever, Infectious Disorder, Lymphadenopathy, Lymphocytosis, Night Sweats, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Richter Syndrome, Secondary Malignant Neoplasm, Thrombocytopenia, Weight Loss
Interventions
Ex Vivo-activated Autologous Lymph Node Lymphocytes, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 19, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

NCT01326923
View directory record Official record
Conditions
Head and Neck Squamous Cell Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 19, 2026, 5:02 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

NCT06449313
View directory record Official record
Conditions
Non-small Cell Lung Cancer Stage III
Interventions
Cemiplimab-Rwlc
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

SentiMag® Intraoperative Comparison in Breast Cancer

NCT02336737
View directory record Official record
Conditions
Breast Cancer
Interventions
SiennaXP, Technetium Tc99m Sulfur Colloid, Isosulfan blue dye
Device · Drug
Lead sponsor
Endomagnetics Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Indocyanine Green Lymphangiography in Identifying Thoracic Duct During Neck Surgery

NCT03532581
View directory record Official record
Conditions
Neck Dissection, Radical Lymph Node Dissection
Interventions
Indocyanine Green Solution, Lymphangiography
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 19, 2026, 5:02 AM EDT
Not yet recruiting No phase listed Observational

Tumor-Lymph Node Mapping

NCT07054944
View directory record Official record
Conditions
Pediatric Solid Tumors, Rhabdomyosarcoma, Sarcoma, Germ Cell Tumor
Interventions
ICG (Indocyanine Green)
Diagnostic Test
Lead sponsor
University of Rochester
Other
Eligibility
1 Month to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer

NCT02138214
View directory record Official record
Conditions
Stage I Papillary Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage III Papillary Thyroid Cancer
Interventions
Thyroidectomy, entral lymph node dissection (CLND), Quality-of-life assessment
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 73 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 19, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection

NCT02509585
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Tc99m tilmanocept
Drug
Lead sponsor
Cardinal Health 414, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
La Jolla, California • Miami, Florida • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer

NCT02131558
View directory record Official record
Conditions
Endometrial Cancer, Sentinel Lymph Node Detection
Interventions
ICG Dye
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 19, 2026, 5:02 AM EDT
Terminated Phase 2 Interventional Results available

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

NCT02408887
View directory record Official record
Conditions
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer
Interventions
Total Thyroidectomy (TT), Prophylactic central neck lymph node dissection (pCND)
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 19, 2026, 5:02 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

NCT00004125
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2016
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 19, 2026, 5:02 AM EDT
Recruiting Phase 2Phase 3 Interventional

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537
View directory record Official record
Conditions
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions
Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2036
U.S. locations
106
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 19, 2026, 5:02 AM EDT